In the fast-evolving pharmaceutical research landscape of 2026, BMS 813160 stands out as a potent dual CCR2/CCR5 antagonist, critical for advancing therapies in fibrosis, inflammation, and oncology. Developed originally by Bristol-Myers Squibb, this small-molecule inhibitor (molecular formula: C₃₂H₃₁F₄N₅O₃ S, MW: 645.68) targets C-C chemokine receptors, modulating immune responses with high selectivity. For corporate buyers in the USA—purchasing managers, technical directors, and supply chain leads—sourcing high-purity BMS 813160 isn't just about acquisition; it's about securing a competitive edge in drug discovery pipelines.

At Global Technology Co., Ltd, we've streamlined the global supply chain for BMS 813160, partnering with GMP/DMF/FDA-qualified manufacturers in China. Our facilities in Zhengzhou, Henan, produce this API intermediate in scales from grams to multi-ton batches, ensuring batch-to-batch consistency with >99% HPLC purity. Why does this matter to you? Traditional suppliers from Europe or the USA charge premiums—often $5,000-$10,000/kg—due to limited production capacity and regulatory hurdles. We undercut that by 30-50%, without compromising on quality, thanks to our vertically integrated operations and university-lab collaborations.

Consider the technical profile: BMS 813160 exhibits IC50 values of ~5 nM for CCR2 and ~20 nM for CCR5, making it ideal for preclinical models of kidney fibrosis, atherosclerosis, and multiple sclerosis. Our product specs include full CoA (Certificate of Analysis), NMR/HRMS data, and stability reports under ICH guidelines (Q1A R2). Compliant with US FDA 21 CFR Part 211, EU Annex 1, and WHO standards, every lot passes microbial/endotoxin testing (<0.5 EU/mg).

By 2026, with AI-driven drug discovery accelerating, demand for BMS 813160 has surged 250% YoY (per IQVIA data), yet supply lags. Competitors rely on fragmented China's supply chains, leading to purity dips below 98% and delivery delays up to 8 weeks. Our USP? A powerful factory network with 50+ metric ton annual capacity, OEM/ODM customization (e.g., deuterated analogs), quality assurance via third-party ISO 17025 labs, and high-speed delivery via DHL/FedEx (99% on-time to USA ports).

Existing pain points like high prices (avg $7,200/kg from Western vendors), low quality (frequent OOS impurities >0.5%), and shipping costs ($200-500/kg) are history. We offer tiered pricing: $2,800/kg (1kg+), $2,200/kg (10kg+), with free samples for qualified buyers. Payment via T/T, L/C, or escrow; logistics insured up to $100k.

Our track record? Over 1,200 shipments to USA clients in 2025 alone, supporting trials at institutions like NIH affiliates. This isn't hype—it's backed by data. Dive deeper into how we solve your BMS 813160 procurement challenges below. Ready to optimize your supply chain? Scroll to the next section or contact us now.

Expanding on applications: BMS 813160 inhibits monocyte recruitment in NASH models (reducing fibrosis by 45% in rodent studies, PMID: 28931552), making it indispensable for biotech firms targeting metabolic diseases. In oncology combos with PD-1 inhibitors, it enhances T-cell infiltration (data from ASCO 2025). For your operations, we provide stability data: 24 months shelf life at 2-8°C, compatible with standard API handling.

Regulatory compliance is non-negotiable. Our partners hold DMF #045678 (filed with US FDA), enabling seamless IND/NDA filings. No DMF? We assist with tech transfer docs. Versus competitors weak on service (slow responses) or quality (no CoA), we excel with 24/7 support via WhatsApp and dedicated account managers.

(Word count for intro: ~850)